285 0

Full metadata record

DC FieldValueLanguage
dc.contributor.author김근호-
dc.date.accessioned2018-01-30T06:17:14Z-
dc.date.available2018-01-30T06:17:14Z-
dc.date.issued2011-01-
dc.identifier.citationThe Korean Journal of Internal Medicine, 2011, 26(1), P.68-75en_US
dc.identifier.issn1226-3303-
dc.identifier.urihttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3056258/-
dc.description.abstractBackground/Aims: Short hemofilter survival and anticoagulation-related life-threatening complications are major problems in systemic anticoagulation with heparin (SAH) for continuous renal replacement therapy (CRRT). The present study examined if regional anticoagulation with citrate (RAC) using commercially available solutions can overcome the associated problems of SAH to produce economical benefits. Methods: Forty-six patients were assigned to receive SAH or RAC. We assessed the coagulation state, clinical outcomes, and adverse events. A Kaplan-Meier analysis was used to estimate hemofilter life span. The economical benefit related to the prolonged hemofilter survival was examined on the basis of the average daily cost. Results: The mean age of patients was 66.5 ± 13.8 years and the majority were male (60.9%). While elective discontinuation was most common cause of early CRRT interruption in the RAC group (34.3%, p < 0.01), hemofilter clotting was most prevalent in the SAH group (82.2%, p < 0.01). The patient metabolic and electrolyte control and survival rate were not different between the two groups. When compared with the RAC group, the anticoagulation-associated bleeding was a major complication in the SAH group (15.0% vs. 61.5%, p < 0.01). Regional anticoagulated hemofilters displayed a significantly longer survival time than systemic anticoagulated hemofilters (59.5 ± 3.8 hr vs. 15.6 ± 1.3 hr, p < 0.01). Accordingly, the mean daily continuous venovenous hemodiafiltration costs in the RAC and SAH groups were $575 ± 268 and $1,209 ± 517, respectively (p < 0.01). Conclusions: RAC prolonged hemofilter survival, displaying an economical benefit without severe adverse effects. The present study therefore demonstrates that RAC, using commercially available solutions, may be advantageous over SAH as a cost-effective treatment in CRRT. (Korean J Intern Med 2011;26:68-75)en_US
dc.language.isoenen_US
dc.publisherThe Korean Association of Internal Medicineen_US
dc.subjectAnticoagulationen_US
dc.subjectCitric aciden_US
dc.subjectRenal replacement therapyen_US
dc.subjectHeparinen_US
dc.titleRegional Anticoagulation with Citrate is Superior to Systemic Anticoagulation with Heparin in Critically Ill Patients Undergoing Continuous Venovenous Hemodiafiltrationen_US
dc.typeArticleen_US
dc.relation.no1-
dc.relation.volume26-
dc.identifier.doi10.3904/kjim.2011.26.1.68-
dc.relation.page68-75-
dc.relation.journalKorean Journal of Internal Medicine-
dc.contributor.googleauthorPark, Joon-Sung-
dc.contributor.googleauthorKim, Gheun-Ho-
dc.contributor.googleauthorKang, Chong Myung-
dc.contributor.googleauthorLee, Chang Hwa-
dc.contributor.googleauthor김근호-
dc.relation.code2012231758-
dc.sector.campusS-
dc.sector.daehakCOLLEGE OF MEDICINE[S]-
dc.sector.departmentDEPARTMENT OF MEDICINE-
dc.identifier.pidkimgh-
Appears in Collections:
COLLEGE OF MEDICINE[S](의과대학) > MEDICINE(의학과) > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE